You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia: Oncology Pharmacist and Nurse Perspectives

  • Authors: Ryan J. Daley, PharmD, BCOP; Katherine L. Byar, MSN, ANP, BC, BMTCN
  • CE Released: 9/19/2022
  • Valid for credit through: 3/19/2023
Start Activity

Target Audience and Goal Statement

This activity is intended for oncology pharmacists, nurses, and nurse practitioners.

The goal of this activity is to provide oncology pharmacists and nurses with enhanced knowledge and competence on the use of asparaginase for the treatment of ALL including types of approved agents, efficacy, toxicity, and approaches for adverse event prevention and management, all of which will help to improve patient outcomes.

Upon completion of this activity, participants will:

  • Explain the rationale for use of asparaginase in the treatment of ALL
  • Recognize the differences among available forms of asparaginase
  • Describe the basis for selecting the best type of asparaginase based on patient-specific factors, and the optimal dose and route of administration
  • Formulate approaches for identifying and mitigating toxicities associated with asparaginase therapy to optimize treatment outcomes


Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Jazz Pharmaceuticals. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.


  • Ryan J. Daley, PharmD, BCOP

    Clinical Pharmacy Specialist, Leukemia
    Memorial Sloan Kettering Cancer Center
    New York, New York


    Disclosure: Ryan J. Daley, PharmD, BCOP, has the following financial relationships:
    Consultant or advisor for: Da Volterra (Paris, France)
    Ownership interest: (less than 5%) in Aprea Therapeutics, Inc.

  • Katherine L. Byar, MSN, ANP, BC, BMTCN

    Nurse Practitioner, Hematologic Malignancy
    Nebraska Medicine
    Fred & Pamela Buffett Cancer Center
    Omaha, Nebraska


    Disclosure: Katherine L. Byar, MSN, ANP, BC, BMTCN, has no relevant affiliations or financial relationships with a commercial interest.

The clinical reviewer, Lisa Holle, PharmD, BCOP, FHOPA, FISOPP, has no relevant affiliations or financial relationships with a commercial interest.

The writer, Thomas Cook, RPh, PhD, has no actual or potential conflicts of interest in relation to this program.  

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

Accreditation Statements

Jointly Provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

    Published: August 26, 2022
    Expires: February 26, 2023

    Type of Activity: Application
    Media: Internet
    Fee Information: There is no fee for this educational activity.
    Estimated time to complete activity: 120 minutes

    If you have questions regarding the certification of this activity, please contact PIM via email at [email protected].


    Please ensure the computer system you plan to use meets the following minimum requirements:

    • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
    • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
    • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
    • Peripherals: Computer speakers or headphones
    • Monitor Screen Resolution: 320 x 480 or higher
    • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia: Oncology Pharmacist and Nurse Perspectives

Authors: Ryan J. Daley, PharmD, BCOP; Katherine L. Byar, MSN, ANP, BC, BMTCNFaculty and Disclosures

CE Released: 9/19/2022

Valid for credit through: 3/19/2023



  1. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi:10.1038/BCJ.2017.53
  2. Douer D, Gökbuget N, Stock W, Boissel N. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022;53:100908. doi:10.1016/J.BLRE.2021.100908
  3. Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(9):1079-1109. doi:10.6004/JNCCN.2021.0042
  4. Juluri KR, Siu C, Cassaday RD. Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy. Blood Lymphat Cancer. 2022;12:55-79. doi:10.2147/BLCTT.S342052
  5. De Morais SB, De Souza TDACB. Human L‑asparaginase: acquiring knowledge of its activation (Review). Int J Oncol. 2021;58(4):11. doi:10.3892/IJO.2021.5191
  6. Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 2016;7(2):62-71. doi:10.4103/0976-500X.184769
  7. Food and Drug Administrtions. [email protected]: FDA-Approved Drugs - Elspar®. Accessed July 8, 2022. 
  8. Chiu M, Taurino G, Bianchi MG, et al. Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front Oncol. 2020;9:1480. doi:10.3389/FONC.2019.01480
  9. Daley RJ, Rajeeve S, Kabel CC, et al. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(1):176-184. doi:10.1080/10428194.2020.1824068
  10. Elspar® (asparaginase) [package insert]. Deerfield, IL: Lundbeck; 2013. 
  11. Palmer E. Lundbeck to stop making cancer drug. FiercePharma. Published September 19, 2012. Accessed June 29, 2022. 
  12. Yadav D, Dewangan HK. PEGYLATION: an important approach for novel drug delivery system. J Biomater Sci Polym Ed. 2021;32(2):266-280. doi:10.1080/09205063.2020.1825304
  13. ASPARLAS™ (calaspargase pegol – mknl) [package insert]. Boston, MA: Servier Pharmaceuticals; 2021. 
  14. ONCASPAR (pegaspargase) [package insert]. Boston, MA: Servier Pharmaceuticals; 2021.
  15. Heo YA, Syed YY, Keam SJ. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79(7):767-777. doi:10.1007/S40265-019-01120-1
  16. ERWINAZE™ (asparaginase Erwinia chrysanthemi) [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; 2019. 
  17. RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; 2021.
  18. Palmer E. FDA warning savages Porton for contamination that led to shortage of Jazz Pharma leukemia drug. Published January 25, 2017. Accessed June 29, 2022. 
  19. Porton BioPharma. Dear Healthcare Professional Letter. Published May 25, 2021. Accessed June 29, 2022. 
  20. Lin T, Hernandez-Illas M, Rey A, et al. A randomized phase I study to evaluate the safety, yolerability, and pharmacokinetics of recombinant erwinia asparaginase (JZP-458) in healthy adult volunteers. Clin Transl Sci. 2021;14(3):870-879. doi:10.1111/CTS.12947
  21. Bender C, Maese L, Carter-Febres M, Verma A. Clinical utility of pegaspargase in children, adolescents and young adult patients with acute lymphoblastic leukemia: a review. Blood Lymphat Cancer. 2021;11:25-40. doi:10.2147/BLCTT.S245210
  22. Sallan S, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia - PubMed. Cancer Res. 1983;43(11):5601-5607.
  23. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161-7167. doi:10.1200/JCO.2005.11.411
  24. Jazz Pharmaceuticals. Jazz Pharmaceuticals announces U.S. FDA Approval of RylazeTM (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma. Published June 30, 2021. Accessed July 7, 2022.
  25. Food and Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approves Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. Published July 12, 2021. Accessed July 7, 2022.
  26. Maese L, Loh ML, Lin T, et al. Initial results from a phase 2/3 study of recombinant erwinia asparaginase (JZP458) in patients with acute lymphoblastic leukemia (ALL)/Lymphoblastic Lymphoma (LBL) who are allergic/hypersensitive to E coli-derived asparaginases. Blood. 2021;138(Supplement 1):2307. doi:10.1182/BLOOD-2021-147023
  27. Maese LD, Loh ML, Choi LMR, et al. Efficacy and safety of intramuscular (IM) recombinant Erwinia asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Children’s Oncology Group (COG) AALL1931 study. J Clin Oncol. 2022;40(16_suppl):7001-7001. doi:10.1200/JCO.2022.40.16_SUPPL.7001
  28. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2002;99(6):1986-1994. doi:10.1182/BLOOD.V99.6.1986
  29. Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991-998. doi:10.1634/THEONCOLOGIST.12-8-991
  30. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218. doi:10.1182/BLOOD.V97.5.1211
  31. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677-1690. doi:10.1016/S1470-2045(15)00363-0
  32. Schore RJ, Devidas M, Bleyer A, et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4. Leuk Lymphoma. 2019;60(7):1740-1748. doi:10.1080/10428194.2018.1542146
  33. Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children’s Oncology Group Study AALL07P4. J Clin Oncol. 2014;32(34):3874-3882. doi:10.1200/JCO.2014.55.5763
  34. Vrooman LM, Blonquist TM, Stevenson KE, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496-3505. doi:10.1200/JCO.20.03692
  35. Li RJ, Jin R, Liu C, et al. FDA Approval Summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults. Clin Cancer Res. 2020;26(2):328-331. doi:10.1158/1078-0432.CCR-19-1255
  36. Geyer MB, Ritchie EK, Rao A V., et al. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021;106(8):2086-2094. doi:10.3324/HAEMATOL.2020.251686
  37. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526-534. doi:10.1038/LEU.2014.229
  38. Siegel SE, Stock W, Johnson RH, et al. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol. 2018;4(5):725-734. doi:10.1001/JAMAONCOL.2017.5305
  39. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843-1849. doi:10.1200/JCO.2007.13.7265
  40. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911-918. doi:10.1200/JCO.2008.18.6916
  41. Huguet F, Chevret S, Leguay T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 Clinical Trial. J Clin Oncol. 2018;36(24):2514-2523. doi:10.1200/JCO.2017.76.8192
  42. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559. doi:10.1182/BLOOD-2018-10-881961
  43. Bigliardi S, Morselli M, Potenza L, et al. Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study. Leuk Lymphoma. 2015;56(3):770-773. doi:10.3109/10428194.2014.933216
  44. Horvat TZ, Pecoraro JJ, Daley RJ, et al. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leuk Res. 2016;50:17-20. doi:10.1016/J.LEUKRES.2016.08.014
  45. An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL). Published October 30, 2019. Accessed July 7, 2022. 
  46. Lee JK, Kang SM, Wang X, et al. HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway. Blood. 2019;133(20):2222-2232. doi:10.1182/BLOOD-2018-12-890236
  47. Haskell CM, Canellos GP. l-asparaginase resistance in human leukemia--asparagine synthetase. Biochem Pharmacol. 1969;18(10):2578-2580. doi:10.1016/0006-2952(69)90375-X
  48. Van Trimpont M, Peeters E, De Visser Y, et al. Novel insights on the use of L-asparaginase as an efficient and safe anti-cancer therapy. Cancers (Basel). 2022;14(4):902. doi:10.3390/CANCERS14040902
  49. van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279-285. doi:10.3324/HAEMATOL.2015.137380
  50. Burke PW, Hoelzer D, Park JH, et al. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO open. 2020;5(5):e000858. doi:10.1136/ESMOOPEN-2020-000858
  51. Erytech. Eryaspase. Published 2022. Accessed July 8, 2022. 
  52. Sternberg A. FDA grants fast track designation to eryaspase in asparaginase hypersensitive ALL. Published July 30, 2021. Accessed July 6, 2022. 
  53. Lynggaard LS, Vaitkeviciene G, Langenskiöld C, et al. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia. Br J Haematol. 2022;197(6):745-754. doi:10.1111/BJH.18152
  54. Modi T, Gervais D. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Invest New Drugs. 2022;40(1):21-29. doi:10.1007/S10637-021-01173-8
  55. Beckett A, Gervais D. What makes a good new therapeutic L-asparaginase? World J Microbiol Biotechnol. 2019;35(10):152. doi:10.1007/S11274-019-2731-9
  56. Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59(7):1624-1633. doi:10.1080/10428194.2017.1397658
  57. Asselin B. Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia. Future Oncol. 2016;12(13):1609-1621. doi:10.2217/FON-2016-0005
  58. Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. Future Oncol. 2022;18(10):1285-1299. doi:10.2217/FON-2021-1288
  59. Huynh VT, Bergeron S. Asparaginase toxicities: identification and management in patients with acute lymphoblastic leukemia. Clin J Oncol Nurs. 2017;21(5):E248-E259. doi:10.1188/17.CJON.E248-E259
  60. Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797-1806. doi:10.1080/10428194.2017.1386305
  61. Pike M, Kulkarni K, MacDonald T. Asparaginase activity monitoring and management of asparaginase hypersensitivity reactions in Canada. J Oncol Pharm Pract. 2021:10781552211055404. doi:10.1177/10781552211055405
  62. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE). Updated April 19, 2021. Accessed July 5, 2022.
  63. Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018;24(4):299-308. doi:10.1177/1078155217701291
  64. Kamal N, Koh C, Samala N, et al. Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. Hepatol Int. 2019;13(5):641-648. doi:10.1007/S12072-019-09971-2
  65. Stock W, Douer D, Deangelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237-2253. doi:10.3109/10428194.2011.596963
  66. Schulte RR, Madiwale M V., Flower A, et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leuk Lymphoma. 2018;59(10):2360-2368. doi:10.1080/10428194.2018.1435873
  67. Blackman A, Boutin A, Shimanovsky A, et al. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract. 2018;24(5):393-397. doi:10.1177/1078155217710714
  68. Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375-380. doi:10.1111/EJH.12600
  69. Oparaji JA, Rose F, Okafor D, et al. Risk factors for asparaginase-associated pancreatitis: a systematic review. J Clin Gastroenterol. 2017;51(10):907-913. doi:10.1097/MCG.0000000000000827
  70. Grace RF, DeAngelo DJ, Stevenson KE, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45(2):306-314. doi:10.1007/S11239-017-1597-7
  71. Kashanian SM, Holtzman NG, Patzke CL, et al. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens. Cancer Chemother Pharmacol. 2021;87(6):817-826. doi:10.1007/S00280-021-04252-Y
  72. Orvain C, Balsat M, Tavernier E, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136(3):328-338. doi:10.1182/BLOOD.2020004919
  73. Grover SP, Hisada YM, Kasthuri RS, et al. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291-1305. doi:10.1161/ATVBAHA.120.314378
  74. Sui J, Zhang Y, Yang L, et al. Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: a case report and literature review. Medicine (Baltimore). 2017;96(46). doi:10.1097/MD.0000000000008715
  75. Rank CU, Lynggaard LS, Als-Nielsen B, et al. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020;10(10):CD013399. doi:10.1002/14651858.CD013399.PUB2
  76. Chen Y, Buhlinger K, Perissinotti AJ, et al. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase. Leuk Lymphoma. June 2022:1-8. doi:10.1080/10428194.2022.2087066
  77. Zwicker JI, Wang TF, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH. J Thromb Haemost. 2020;18(2):278-284. doi:10.1111/JTH.14671
  78. Bade NA, Lu C, Patzke CL, et al. Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring, and management. J Oncol Pharm Pract. 2020;26(1):74-92. doi:10.1177/1078155219838316
  79. Cooper SL, Young DJ, Bowen CJ, et al. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797. doi:10.1002/PBC.27797
  80. Managing Stress. Published July 2019. Accessed July 8, 2022. 
  81. National Cancer Institute. Psychological Stress and Cancer. Published December 10, 2012. Accessed July 8, 2022. 
  82. Asparaginase - Drug Information. Accessed July 8, 2022. 
  83. Memorial Sloan Kettering Cancer Center. Pegaspargase: Pediatric Medication. Published 2022. Accessed July 8, 2022. 
  84. Memorial Sloan Kettering Cancer Center. Asparaginase (Erwinia): Pediatric Medication. Published 2022. Accessed July 8, 2022. 
  85. UPMC Hillman Cancer Center. Asparaginase (Erwinaze). Published 2022. Accessed July 8, 2022. 
  86. Goodwillie B, Renteria C. Nursing-pharmacy collaboration: find the sweet spot. Fierce Healthcare. Published February 26, 2015. Accessed July 8, 2022.
  87. Devaux M, Boulin M, Mounier M, et al. Clinical and economic Impact of a multidisciplinary follow-up program in lymphoma patients. Cancers (Basel). 2022;14(10):2532. doi:10.3390/CANCERS14102532
  88. Schiff GD, Galanter WL, Duhig J, et al. A prescription for improving drug formulary decision making. PLoS Med. 2012;9(5):1-7. doi:10.1371/journal.pmed.1001220
  89. Baker D, Barrington C, Cannon E, et al. AMCP Partnership Forum: principles for sound pharmacy and therapeutics (P&T) committee practices: what’s next? J Manag Care Spec Pharm. 2020;26(1):48-53. doi:10.18553/jmcp.2020.26.1.48
  90. Marini BL, Brown J, Benitez L, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019;60(12):2854-2868. doi:10.1080/10428194.2019.1608530
  91. Wind A, van der Linden C, Hartman E, et al. Patient involvement in clinical pathway development, implementation and evaluation - A scoping review of international literature. Patient Educ Couns. 2022;105(6):1441-1448. doi:10.1016/J.PEC.2021.10.007


« Return to: Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia: Oncology Pharmacist and Nurse Perspectives
  • Print